Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy

Nobuaki Sato, Masaki Shiota, Ken ichiro Shiga, Ario Takeuchi, Junichi Inokuchi, Katsunori Tatsugami, Akira Yokomizo, Hirofumi Koga, Akito Yamaguchi, Seiji Naito, Masatoshi Eto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To analyze the association between smoking and oncological outcome after radical prostatectomy in patients with prostate cancer.Methods: This study included men who underwent radical prostatectomy between 2003 and 2013. The association of clinicopathological factors with smoking status and the prognostic significance of clinicopathological factors and smoking status on biochemical recurrence (BCR) were evaluated.Results: Of the 1165 included patients, 226 (19.4%) were current smokers and 939 (80.6%) were nonsmokers. The median observation period was 39 months (interquartile range, 15-75 months). Current smokers were younger than nonsmokers and had higher PSA levels, higher biopsy and pathological Gleason scores, and more frequent lymph-node involvement than nonsmokers. Pathological Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margin, lymph-node involvement, and current smoking (hazard ratio [95% confidence interval]; 1.31 [1.00-1.72], P = 0.046) were identified as significant risk factors of BCR on univariate analysis. However, smoking status was not an independent predictive marker on multivariate analysis.Conclusions: Current smokers had adverse clinicopathological characteristics including high PSA level, high Gleason score, and lymph node involvement, suggesting that smoking promoted the progression of prostate cancer.

Original languageEnglish
Article numberhyx013
Pages (from-to)453-457
Number of pages5
JournalJapanese journal of clinical oncology
Volume47
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Prostatectomy
Prostatic Neoplasms
Smoking
Neoplasm Grading
Lymph Nodes
Recurrence
Seminal Vesicles
Multivariate Analysis
Observation
Confidence Intervals
Biopsy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy. / Sato, Nobuaki; Shiota, Masaki; Shiga, Ken ichiro; Takeuchi, Ario; Inokuchi, Junichi; Tatsugami, Katsunori; Yokomizo, Akira; Koga, Hirofumi; Yamaguchi, Akito; Naito, Seiji; Eto, Masatoshi.

In: Japanese journal of clinical oncology, Vol. 47, No. 5, hyx013, 01.05.2017, p. 453-457.

Research output: Contribution to journalArticle

@article{921fecbd5f644d7d870c89a3fac71201,
title = "Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy",
abstract = "Objective: To analyze the association between smoking and oncological outcome after radical prostatectomy in patients with prostate cancer.Methods: This study included men who underwent radical prostatectomy between 2003 and 2013. The association of clinicopathological factors with smoking status and the prognostic significance of clinicopathological factors and smoking status on biochemical recurrence (BCR) were evaluated.Results: Of the 1165 included patients, 226 (19.4{\%}) were current smokers and 939 (80.6{\%}) were nonsmokers. The median observation period was 39 months (interquartile range, 15-75 months). Current smokers were younger than nonsmokers and had higher PSA levels, higher biopsy and pathological Gleason scores, and more frequent lymph-node involvement than nonsmokers. Pathological Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margin, lymph-node involvement, and current smoking (hazard ratio [95{\%} confidence interval]; 1.31 [1.00-1.72], P = 0.046) were identified as significant risk factors of BCR on univariate analysis. However, smoking status was not an independent predictive marker on multivariate analysis.Conclusions: Current smokers had adverse clinicopathological characteristics including high PSA level, high Gleason score, and lymph node involvement, suggesting that smoking promoted the progression of prostate cancer.",
author = "Nobuaki Sato and Masaki Shiota and Shiga, {Ken ichiro} and Ario Takeuchi and Junichi Inokuchi and Katsunori Tatsugami and Akira Yokomizo and Hirofumi Koga and Akito Yamaguchi and Seiji Naito and Masatoshi Eto",
year = "2017",
month = "5",
day = "1",
doi = "10.1093/jjco/hyx013",
language = "English",
volume = "47",
pages = "453--457",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy

AU - Sato, Nobuaki

AU - Shiota, Masaki

AU - Shiga, Ken ichiro

AU - Takeuchi, Ario

AU - Inokuchi, Junichi

AU - Tatsugami, Katsunori

AU - Yokomizo, Akira

AU - Koga, Hirofumi

AU - Yamaguchi, Akito

AU - Naito, Seiji

AU - Eto, Masatoshi

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Objective: To analyze the association between smoking and oncological outcome after radical prostatectomy in patients with prostate cancer.Methods: This study included men who underwent radical prostatectomy between 2003 and 2013. The association of clinicopathological factors with smoking status and the prognostic significance of clinicopathological factors and smoking status on biochemical recurrence (BCR) were evaluated.Results: Of the 1165 included patients, 226 (19.4%) were current smokers and 939 (80.6%) were nonsmokers. The median observation period was 39 months (interquartile range, 15-75 months). Current smokers were younger than nonsmokers and had higher PSA levels, higher biopsy and pathological Gleason scores, and more frequent lymph-node involvement than nonsmokers. Pathological Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margin, lymph-node involvement, and current smoking (hazard ratio [95% confidence interval]; 1.31 [1.00-1.72], P = 0.046) were identified as significant risk factors of BCR on univariate analysis. However, smoking status was not an independent predictive marker on multivariate analysis.Conclusions: Current smokers had adverse clinicopathological characteristics including high PSA level, high Gleason score, and lymph node involvement, suggesting that smoking promoted the progression of prostate cancer.

AB - Objective: To analyze the association between smoking and oncological outcome after radical prostatectomy in patients with prostate cancer.Methods: This study included men who underwent radical prostatectomy between 2003 and 2013. The association of clinicopathological factors with smoking status and the prognostic significance of clinicopathological factors and smoking status on biochemical recurrence (BCR) were evaluated.Results: Of the 1165 included patients, 226 (19.4%) were current smokers and 939 (80.6%) were nonsmokers. The median observation period was 39 months (interquartile range, 15-75 months). Current smokers were younger than nonsmokers and had higher PSA levels, higher biopsy and pathological Gleason scores, and more frequent lymph-node involvement than nonsmokers. Pathological Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margin, lymph-node involvement, and current smoking (hazard ratio [95% confidence interval]; 1.31 [1.00-1.72], P = 0.046) were identified as significant risk factors of BCR on univariate analysis. However, smoking status was not an independent predictive marker on multivariate analysis.Conclusions: Current smokers had adverse clinicopathological characteristics including high PSA level, high Gleason score, and lymph node involvement, suggesting that smoking promoted the progression of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85027165739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027165739&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyx013

DO - 10.1093/jjco/hyx013

M3 - Article

C2 - 28184442

AN - SCOPUS:85027165739

VL - 47

SP - 453

EP - 457

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 5

M1 - hyx013

ER -